company background image
BIIB

Biogen NasdaqGS:BIIB Stock Report

Last Price

US$213.57

Market Cap

US$31.3b

7D

5.9%

1Y

-37.2%

Updated

27 Jun, 2022

Data

Company Financials +
BIIB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BIIB Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.

Biogen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$213.57
52 Week HighUS$372.12
52 Week LowUS$187.16
Beta0.42
1 Month Change3.57%
3 Month Change-0.64%
1 Year Change-37.24%
3 Year Change-9.31%
5 Year Change-21.63%
Change since IPO6,826.60%

Recent News & Updates

Jun 20
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

BIIBUS BiotechsUS Market
7D5.9%10.3%6.3%
1Y-37.2%-24.5%-18.8%

Return vs Industry: BIIB underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: BIIB underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement5.0%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: BIIB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BIIB's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19789,610Michel Vounatsoshttps://www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.

Biogen Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market CapUS$31.28b
Earnings (TTM)US$1.45b
Revenue (TTM)US$10.82b

21.6x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIIB income statement (TTM)
RevenueUS$10.82b
Cost of RevenueUS$2.39b
Gross ProfitUS$8.43b
Other ExpensesUS$6.98b
EarningsUS$1.45b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.90
Gross Margin77.95%
Net Profit Margin13.40%
Debt/Equity Ratio64.8%

How did BIIB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Other financial metrics that can be useful for relative valuation.

BIIB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.2x
Enterprise Value/EBITDA9.4x
PEG Ratio9.4x

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

BIIB PE Ratio vs Peers
The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average112.9x
BMRN BioMarin Pharmaceutical
400.1x48.1%US$15.7b
INCY Incyte
18.4x27.7%US$17.1b
GILD Gilead Sciences
17.5x8.3%US$78.8b
UTHR United Therapeutics
15.9x11.2%US$10.9b
BIIB Biogen
21.6x2.3%US$31.3b

Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (112.9x).


Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: BIIB is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the US Biotechs industry average (15.4x)


Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.6x
Fair PE Ratio23x

Price-To-Earnings vs Fair Ratio: BIIB is good value based on its Price-To-Earnings Ratio (21.6x) compared to the estimated Fair Price-To-Earnings Ratio (23x).


Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIB ($213.57) is trading below our estimate of fair value ($468.21)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: BIIB is poor value based on its PEG Ratio (9.4x)


Discover undervalued companies

Future Growth

How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIIB's forecast earnings growth (2.3% per year) is above the savings rate (1.9%).

Earnings vs Market: BIIB's earnings (2.3% per year) are forecast to grow slower than the US market (13.9% per year).

High Growth Earnings: BIIB's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIIB's revenue (0.1% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: BIIB's revenue (0.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIIB's Return on Equity is forecast to be low in 3 years time (15.8%).


Discover growth companies

Past Performance

How has Biogen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIIB has a large one-off loss of $1.2B impacting its March 31 2022 financial results.

Growing Profit Margin: BIIB's current net profit margins (13.4%) are lower than last year (23.9%).


Past Earnings Growth Analysis

Earnings Trend: BIIB's earnings have declined by 4.9% per year over the past 5 years.

Accelerating Growth: BIIB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIIB had negative earnings growth (-51.9%) over the past year, making it difficult to compare to the Biotechs industry average (96.9%).


Return on Equity

High ROE: BIIB's Return on Equity (13.7%) is considered low.


Discover strong past performing companies

Financial Health

How is Biogen's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BIIB's short term assets ($7.9B) exceed its short term liabilities ($3.9B).

Long Term Liabilities: BIIB's short term assets ($7.9B) do not cover its long term liabilities ($8.4B).


Debt to Equity History and Analysis

Debt Level: BIIB's net debt to equity ratio (31.4%) is considered satisfactory.

Reducing Debt: BIIB's debt to equity ratio has increased from 56.8% to 64.8% over the past 5 years.

Debt Coverage: BIIB's debt is well covered by operating cash flow (41.7%).

Interest Coverage: BIIB's interest payments on its debt are well covered by EBIT (12.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Biogen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIIB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Michel Vounatsos (59 yo)

5.42yrs

Tenure

US$17,689,665

Compensation

Mr. Michel Vounatsos serves as Director at PerkinElmer, Inc. since March 1, 2020. He has been the Chief Executive Officer and Director of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chie...


CEO Compensation Analysis

Compensation vs Market: Michel's total compensation ($USD17.69M) is above average for companies of similar size in the US market ($USD13.43M).

Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BIIB's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: BIIB's board of directors are seasoned and experienced ( 12.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biogen Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biogen Inc.
  • Ticker: BIIB
  • Exchange: NasdaqGS
  • Founded: 1978
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$31.278b
  • Shares outstanding: 146.45m
  • Website: https://www.biogen.com

Number of Employees


Location

  • Biogen Inc.
  • 225 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.